Copyright
©The Author(s) 2019.
World J Diabetes. Feb 15, 2019; 10(2): 114-132
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
S. No | Search terms |
1 | NAFLD |
2 | Nonalcoholic fatty liver disease |
3 | Non-alcoholic fatty liver disease |
4 | Non alcoholic fatty liver disease |
5 | NASH |
6 | Non-alcoholic steatohepatitis |
7 | Nonalcoholic steatohepatitis |
8 | Non alcoholic steatohepatitis |
9 | Fatty liver |
10 | 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 |
11 | Type 2 diabetes mellitus |
12 | Type 2 diabetes |
13 | Diabetes mellitus type 2 |
14 | Diabetes type 2 |
15 | 11 OR 12 OR 13 OR 14 |
16 | SGLT-2 inhibitors |
17 | Sodium glucose cotransporter-2 inhibitors |
18 | SGLT-2 |
19 | SGLT2 |
20 | SGLT 2 |
21 | Canagliflozin |
22 | Dapagliflozin |
23 | Empagliflozin |
24 | Ipragliflozin |
25 | Luseogliflozin |
26 | Tofogliflozin |
27 | Sotagliflozin |
28 | Remogliflozin |
29 | Ertugliflozin |
30 | Sergliflozin |
31 | 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 |
32 | 10 AND 15 AND 31 |
- Citation: Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132
- URL: https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i2.114